This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe

Press Releases

Take a look at a selection of our recent media coverage:

Network meta-analysis confirms superiority of biologics to small molecules in plaque psoriasis

7th May 2021

A number of systemic treatments are available for plaque psoriasis but there are few direct comparative studies, making assessment of their relative effectiveness more difficult.

Psoriasis is now considered to be an immune-mediated, chronic inflammatory disease which can affect both the skin and joints. There is no cure for the disease and while treatments are able to provide satisfactory control, long-term management is required. Although most patients have mild to moderate disease which can be controlled with topical therapies, around 20–30% of patients have moderate to severe disease, that requires systemic treatment. Oral therapies include ciclosporin, methotrexate, acitretin, apremilast and fumaric esters. In addition, there are now several biological therapies available and which have revolutionised the treatment of more severe disease. These have been broadly categorised based on their mode of action, e.g., anti-interleukin -17 (IL-17), e.g., secukinumab, ixekizumab and brodalumab, anti-IL-12/23, e.g., ustekinumab, anti-IL-23, e.g., guselkumab and anti-tumour necrosis factor (TNF), e.g., infliximab, adalimumab, etanercept. In the absence of direct head-to-head trials, a network meta-analysis (NMA), which uses both direct and indirect information, is invaluable to identify the relative efficacy of the available treatments. This was the method used by a team responsible for a Cochrane review of systemic treatments in psoriasis. The authors included only randomised trials in adults (18 years and over) with moderate-to-severe psoriasis in comparison to placebo and set the primary outcome as the proportion of participants achieving a psoriasis area and severity index (PASI) score of 90. The PASI is a measure of disease severity, ranging from 0 to 72 and with higher scores representing more severe disease. A PASI90 indicates that participants achieved a 90% improvement in disease severity from baseline.

The analysis included 158 studies with 57,831 participants (67.2% male) with an average age of 45 years and a mean baseline PASI of 20. At a class level, the anti-IL-17, anti-IL12/23, anti-IL23 and anti-TNF agents were all significantly more effective at achieving a PASI90 compared to the non-biologics. The NMA showed that infliximab, ixekizumab and secukinumab were the most effect biologics and with a similar clinical effectiveness.
The authors noted that a limitation was how the evaluations were limited to induction therapy, i.e., from 8 to 24 weeks after randomisation which was insufficient to assess the longer-term outcomes.

They also commented that the data did not help identify which patients were more suited to the smaller molecules and how in future pragmatic trials that involve switching between treatments, dosage adjustments, are needed to evaluate these drugs in clinical practice.

Sbidian E et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Sys Rev 2021

Approximately a fifth of people across the world would refuse a COVID-19 vaccine

14th December 2020

As a COVID-19 vaccine is rolled out across the UK and the US, a meta-analysis of international studies suggests a sizeable proportion of people are unwilling to be vaccinated which has important implications for the effectiveness of a vaccination programme.

It is fairly well established that a route out of the restrictions imposed on individuals because of COVID-19 would be through widespread vaccination once a suitable product becomes available. Early in the pandemic, several studies sought to ascertain people’s perceptions on whether they would be willing to receive a vaccination against the virus. Such information is of vital importance because it is believed that a large proportion of a country’s population needs to be vaccinated for the program to be fully effective. The earliest data was positive, with a large majority of those surveyed, stating that they were likely to want to be vaccinated. However, given the pace with which vaccines have entered developed, there has been a good deal of misinformation circulated on social media, leading to potential mistrust in the safety of vaccines which has been produced and tested in such a short space of time than normal.

Given this potential uncertainty, a team led by researchers from the Department of Psychology, University of Liverpool, set out to systematically review all the available studies undertaken to examine the percentage of the population intending to be either vaccinated or intending to refuse it once available. Included studies were required to have used a nationally representative sample (e.g. based on age, gender, education level etc) and having a sample size greater than 1000 participants from the same country though any studies from non-general public samples e.g., healthcare professionals, students, were excluded. In addition, all eligible studies had to include a question that measured willingness to use a vaccine for COVID-19 once available and these studies had to report the outcome for each option, e.g., yes vs no, or willing vs unsure vs unwilling.

A total of 20 articles reporting on 28 samples were included which were undertaken in 13 different countries. The size of each sample varied from 1,000 to 7,547 with a median of 1,198. In addition, samples were collected in the early phase of the pandemic (March – May 2020) or later (June 2020 and onwards). Interestingly, the proportion of respondents willing to be vaccinated decreased over time (79% early phase studies vs 60% later studies), whereas the proportion not willing to be vaccinated increased (12% early studies vs 20% later studies). In contrast, the proportion of individuals who stated that they were unsure did not change over time. There was also a persistent trend relating to vaccination intentions: being female, younger, of lower income/education level or belonging to an ethnic minority were all associated with a reduced likelihood of wanting to be vaccinated.

The authors called for an urgent need to address vaccination hesitancy to promote widespread uptake of the vaccine.

Robinson E et al. International estimates of intended uptake and refusal of COVID-19 vaccines: a rapid systematic review and meta-analysis of large nationally representative samples. MedRxiv 2020